Feel nice and relaxed, like a nightclub. But that is what is going on here. It is a great time here at the UBS Biopharma Conference. I am Michael Yee, Senior Managing Director and Biotech Analyst here at UBS, and we are excited to have our next session. I have the CEO of Allogene Therapeutics, Zachary Roberts. A pleasure to have you here today. Thank you so much.
Thank you.
You guys recently reported earnings, about a week ago. I lose track of time and space, being an analyst, but you just reported. So maybe it would be a great opportunity, Zach, if you start with some of the highlights about Allogene coming away from the earnings, which is continuing to execute on your pivotal phase III study in frontline maintenance, DLBCL. And also, recently you had some autoimmune disease, right? So maybe you could just give us a brief summary of some of those highlights, over the last two weeks, and we could go into some of the details about that.
Absolutely. So I will start with the 329 data. So, we shared that data earlier this month, last week, and that data illustrated, I think, what was very interesting observations that we set up with the design of the product and of the study, where we were able to show improvements in symptoms in patients with diffuse cutaneous scleroderma, without any lymphodepletion at all. So, we are just giving our ALLO-329, and those patients got better just with cells alone, stopping all their previous treatments. Lots to cover from that data release. I think very interesting early proof of concept data for ALLO-329 in theâ
We'll talk about that. Okay, an allogeneic CAR T for the treatment of autoimmune disease, of which you have presented some patients treated with lymphodepletion, with low-dose lymphodepletion, and no lymphodepletion.
Correct.
We'll talk a little bit about that, but you felt that the data are quite promising.
Very promising.
Particularly because there could be no lymphodepletion.
Correct.
Okay. We will go in a little bit of that.
Yep.
That was an announcement last week.
Yes. Then, just before that was earnings.
Okay.
Of course, the topic of conversation always at the top of everyone's list at earnings time is our pivotal program, ALPHA3, with cema-cel in MRD-positive diffuse large B-cell lymphoma. There at the earnings, we announced good progress in the execution of that study, maintaining all the prior guidances around timeline to enrollment and so forth. We are very, very pleased with how that program is unfolding.
So, let's go into a little bit about that. To be fair, this is in a pivotal study. And so you are enrolling in this pivotal, I say frontline maintenance, DLBCLâ
Consolidation.
âconsolidation. And you're enrolling, and there is a potential interim update in the middle of 2027. What is the guidance for full enrollment? How are you doing on the enrollment? What is the timing of the enrollment, and what drives this update in the middle of the year? I say update because I am not actually sure. Did you say it is an interim analysis, or there is an update? So what is the timing of all of this, and what drives this update?
Yeah. So, the update that is scheduled to occur in the middle of next year is, in fact, an interim analysis.
Okay.
It was a pre-specified analysis looking at the primary endpoint of the trial. The primary analysis itself on that same endpoint is expected roughly a year later, so mid-2028.
Okay.
The drivers of the timing of that update, that interim analysis, are, of course, enrollment. This is an event-driven study, so we need to accrue a target number of events to actually trigger that analysis.
Okay.
That itself is dependent on a few factors. First and foremost, pace of enrollment, but also the timing of the events. The faster the events occur, the earlier that that analysis is likely to happen. Of course, the converse is also true.
Without getting people too much confused just yet, but we'll walk through it. It's not necessarily good to have fast events too, because fast events, because you don't know which arm.
That is true, because we're blinded to the events coming in. You're never really quite sure what a quick accrual of events means versus a prolonged enrollment.
Yeah. For this audience here, I appreciate that not every single investor is all caught up in the exact details of what's going on at Allogene. Part of the idea here is to explain what's going on and why this is important, is that in first-line DLBCL, you're getting R-CHOP, but many people who have a complete response still had MRD positivity. There's evidence of the cancer in the bone marrow. What you are trying to do is convert those people from MRD positive to negative by giving them this CAR T therapy rather than just watching and waiting.
Exactly.
Because if you still have cancer and you just watch and wait, the cancer is going to come back, and now you have metastatic disease.
Correct.
You need to go to something else. That is what you're trying to prevent?
Absolutely.
The phase III that is running is trying to determine how many, if you can slow, events, which is event-free survival. Correct me if I'm wrong. Event-free survival would be preventing the recurrence of the cancer from coming back. In order to do that, y ou are treating patients, and we want to prevent the events. What is the expectation for what the event rate happens if you just watch and wait versus if you get the drug? What type of effect do you think you're going to have? Because we've done some analysis around calculating how many events. First of all, have you said how many events have to happen?
We have not.
Okay, you haven't said that. We have an estimate. But what is the event rate trajectory for the placebo arm?
Yeah. Thank you for taking a step back to describe the trial. And you really nailed it. What we're trying to do is fundamentally alter how we take care of patients with diffuse large B-cell lymphoma and related non-Hodgkin's lymphomas, right? Currently, the standard of care is you give R-CHOP or Pola-R-CHP. They're really only two regimens, and there's little variants of each, butâ
Yeah, like Pola's just approved. It's not a standard care, but it's an option.
Yeah. There are variants of R-CHOP, like R-EPOCH, but essentially it is the same regimen that you give everybody. The reason that these regimens are widely given is they are highly efficacious. About 90% of patients will actually achieve a remission.
Most of those patients will be cured, about two-thirds.
Which means one-third will eventually progress. That one-third of patients is the entire relapse refractory population that all the CAR T-cells that are approved, it is in that group, the bispecific regimens and so forth. It is in all those patients who eventually go on to experience a disease progression. ALPHA3 is designed to identify those patients who are at risk of disease progression using this highly sensitive MRD test that you referenced. We administer this MRD test as soon as those patients complete their front line. If we detect residual disease, those are the patients that we then will enroll into the trial and either give a dose of off-the-shelf CAR T-cells or watch and wait.
Your question was how fast these events come in. What we know from now a growing body of published work of MRD-positive patients who are just currently being observed, this is all retrospective data, is that it is a median of about four to six months until you have your disease progression. It tends to happenâ
Four to six months, and the placebo arm, it's not even placebo, it's watch and wait.
Watch and wait.
There's no treatment.
There's no treatment.
Yeah, there's no treatment. Four to six monthsâ
Four to six months.
âis the median time for an event to happen.
Correct. These patients are This is an emergency.
They are going to basically. They are now metastatic.
Right.
Basically, the disease has recurred, it is growing, and they basically would go seek now a second-line option.
Correct.
Which is basically autologous CAR T.
If they are lucky, right? Only about 15% of patients will actually see a CAR T.
Right.
85% of patients will get something else.
Yeah. Has that always been on? I thought it was like a year. Four to six months is what you think the placebo arm is?
No. If you look at all of the data that has been published with ultra-sensitive ctDNA-based MRD tests, whether it is the test that we are using, which is a test called CLARITY, Adaptive, clonoSEQ test, you look at those curves, the median is about six months.
Okay. When you are giving the off-the-shelf CAR T, allogeneic, you believe that you are converting X amount of people from MRD positive to negative. Tell me what you think that number is. Of those are the people that obviously will be benefiting from the disease. Do I have that right?
Correct. Yeah. This gets to the data that we released earlier this year in April. This was a pre-specified interim, we call it a futility analysis.
Futility, yep.
This was the reason that we performed this early analysis was really, this type of a trial had not been done before, this idea of consolidating an MRD-positive remission. We wanted to take an early look to make sure that this hypothesis was sound and that we weren't seeing unacceptable safety profile, because these patients are in remission, right? This was kind of a new set ofâ
And we're giving them a CAR T therapy.
Correct.
They're generally, in layman's terms, somewhat healthy.
They're as healthy as they've been since they received their diagnosis, right? This is a big intervention for them, right? It's based on a test itself which has not yet been proven. There was lots of great reasons for us to have this interim futility look, so we performed it. It was at 12 patients randomized into each arm, so relatively small number of patients. What we saw in that interim analysis was quite definitive that we're on the right track. About 60%, 58% of patients, seven out of 12, who received cema-cel went from MRD positive to MRD negative at the time of the data cut.
Okay.
Conversely, in the observation arm, only two out of 12 patients achieved MRD negativity at the time of the data cut.
Okay.
Clearly we're able to, based on these data, affect the eradication of MRD.
At least five out of the 12, a difference of five over 12, seven versus five patients divided by 12, had a significantâ
42%.
â42% of people are having a benefit in this arm versus that arm. That 42%, or let's call it about half the patients, are having a significant change in the biology of their disease that you are now MRD negative.
Correct.
There's no evidence of disease, so they should not come back to metastatic.
We know that patients who achieve MRD negativity tend to have excellent outcomes. Only about 10% of those patients will ever hear from their lymphoma again.
Wow.
If you can go from positive to negative, you are probably cured. Now, we have to run this study and see what the final results are, but we found this to be very encouraging. But the other part of the equation, Mike, is the safety, right? As I mentioned, these patients are in remission, they're healthy, they don't want to experience a bad safety outcome when their PET scan is clean. As interesting to us as the efficacy was, the safety was truly potentially transformational. We had no cases of CRS of any grade, no cases of ICANS of any grade, no hospitalizations for toxicity, no tocilizumab, no steroids.
This was an outpatient regimen.
We were actually giving it in community practices.
About a third of the patients received their infusions in practices that were defined as community, including some had never given CAR T before.
What we are trying to achieve in ALPHA3 is not simply can we improve lymphoma outcomes, but can we do it in community practices where the majority of these patients receive their care?
If you are having the control arm progress in around five months, you said four to six, so I can model that out, five months. And your drug you are giving and you are affecting approximately, you said how many percent convert?
58%.
58%. And basically 90% of those 58%, the disease is not coming back. That is the general biology and evidence. Can you just model out that percent, and it is basically 58% or 90% of 58% is approximately 54%. So only 54% of the people are never going to progress. And so you could pretty much model that out, and therefore you believe you will have a significant delta on event-free survival. One arm is pretty fast.
Yes.
The other arm, more than half the patients are converting, and therefore they're never going to progress.
That is the hope. That is the reason that we designed the study the way that we did.
Okay. So then what, at the interim analysis in the middle of the year, how should we think about Allogene's design such that, okay, well, we think it's going to hit, but we also have designed it such that it's based on a certain number of events, and then there's a certain amount of alpha spend at an interim because you want to There's many reasons you do an interim. You want to do an interim for safety and efficacy, also to save time, and you don't have to go the full two years to enroll all of these patients if you know it's going to be positive after enrolling half the patients. Saves a lot of time and money.
But on the other hand, if you only take a small amount of alpha because you don't want to jeopardize the whole study, then it may not have enough because it's only a small alpha. So how did you think about that when you designed this, how much alpha to spend, but not spending too much because you don't want to ruin the study?
Well, when we wrote the study originally, we had allocated the alpha using the O'Brien-Fleming method, so that by definition leaves the lion's share of alpha for the primary analysis. The main rationale for that is you don't want to end up dividing your opportunity to show a positive study in a way that prioritizes speed over certainty. That imbalance is baked in by design because first and foremost, we think that this is going to be a positive trial.
Of course, we have to complete the study and see. But the last thing we want to do is end up with a technical failure for a reason that has to do with the study design.
The timing of the analysis, or anything else, right? At the end of the day, if waiting another 6-12 months for the final analysis means that we have a registerable package versus rushing it and then ending up with not enough data to convince the agencies that this is worth approving a marketing application for.
At the end of the day, this will be, if we're successful, the first allogeneic CAR T-cell ever approved.
In a novel indication, in a way that may change practice in a very significant way. With that opportunity in front of us, we really have to make sure that this is done perfectly at each and every step.
Okay. The company designed it to only take a small amount of alpha because you just said you do not want to jeopardize the overall result ultimately. When we get to this event in the middle of the year, and UBS has their own estimates as to approximately 50% of the enrollment, but can you just help us a little bit out because you have not given much information at all? In order for investors to make investments, they need to have some framework around what would happen at the middle of the year. Like, how many patients or how many events would have to happen such that an interim would be worth it? We look at typical interims, typically it is around 50% of the events. Is that in the ballpark?
Generally speaking, you are in the ballpark.
Okay. Based on that number of events, we would not want to take too much alpha. Typically, we see, since we just did a huge analysis on Moderna's interim analyses, they are using 0.025, but that is one-quarter of their 0.1, so I need to adjust for that for you. Approximately one-quarter of the alpha spend, I am assuming you are using 0.05, but one-quarter of the alpha spend. Is that in the general vicinity of typical phase III cancer studies?
That would be on the high end.
High end.
In my experience.
Okay.
Yeah.
All right. Therefore, because one is using only a small amount, less than a quarter, therefore investors should not necessarily expect, if it does stop early, that is a huge positive, but if it does not, it is mostly because of an alpha spend issue, and that you will get more power ultimately for the end because you did power this ultimately for the completion of it, and you do not want to blow up a study because you did not ultimately use too much at the interim. You agree with that?
I would agree with that 100%. In our minds, what matters most here is a positive study that leads to a marketing approval of cema-cel. How you allocate the alpha and when you time the analyses, that should not in any way, shape, or form jeopardize that ultimate goal.
Okay.
That is how we viewed it.
When would completion of enrollment finish such that we would know that you have all the patients in, so from a capital perspective, you certainly can finish the study? How much line of sight do you have on completing enrollment of the study?
End of 2027 is what is anticipated.
And you feel very good about that line of sight?
We do.
Okay. We will look forward to those updates. Again, we are still doing some of our analysis around it because you gave out some of the numbers as to how many patients would then turn from positive to negative, and those are the percent of patients that should benefit. Just to be clear, if you do not turn from positive to negative, it would not be any different than placebo, is that right? Even if you are getting the drug, but you did not convert, it is a very small amount of cells that have cancer, so it is going from small to a little bit small, but not zero. You should not get any better.
I think it is reasonable to assume that in the construct in which cema-cel is able to turn a positive patient negativeâ
Yeah.
âthere is efficacy of these allogeneic cells in the patient, right? I think we've established that in the first interim analysis. I think it's very reasonable for us to assume that even patients who may not turn negative may actually derive some EFS benefit. I think that's a very fair assumption.
What's the biology around that? Because isn't it fairly low levels of cancer, and then you're just going to a little bit lower level, but it's not eliminated, which that's the whole point of MRD negativity. In fact, to be fair, that's why the FDA even accepts it for myeloma.
True.
Becauseâ
It's prognostic.
âthere's no evidence of cancer in the bone marrow cells.
It may be a modest improvement, but even if it adds two or three months to EFS on that fraction of patients who do not clear, that will credit towards the endpoint. I think it is reasonable to assume that there will be a benefit.
One of the other pieces of evidence, as people have tried it, because the science all makes sense, but is there clinical evidence, is that in DLBCL, correct me if I am wrong, but the autologous have shown benefits in later line DLBCL. Is that correct?
In relapse or refractory.
Yeah, correct. Tell me about that data. Also, yeah, so tell me about that data and that support, because that was even in bulkier disease.
I see what you mean. Yeah.
Yeah. What was the evidence?
Yeah. Both YESCARTA and BREYANZI, the two main CAR-Ts in the relapse refractory setting, have now shown data that illustrates that achievement of MRD negativity carries a very strong positive prognostic sign. Patients who achieve that MRD negativity post-BREYANZI or YESCARTA tend to be the ones with durable complete remissions. Not 100%, but the majority of those patients will actually be cured of their lymphoma.
You mentioned this 90% number, that 90% of them will never see their hematologist again if they get it. Was that from that info, or that is like what percent of people?
That's overall. That stat that I pointed out was the overall frontline outcomes. In the relapse refractory, the numbers shift a little bit.
Right.
Once you've had relapses, you're kind of in trouble. And in fact, in most cases, those patients unfortunately will die from lymphoma, even if they do receive YESCARTA or BREYANZI, which again, only a fraction of them do. It still is less than half of those patients will have durable survival. The ones that do tend to achieve MRD negativity in the months following the CAR T infusion. And the interesting part of that data is that, in fact, if you look specifically the TRANSFORM data, so this is BREYANZI in the second line, there was about a 25% delta between MRD negativity in the two arms, CAR T versus standard of care. However, that led to an EFS of under 0.4 for a hazard ratio.
Yeah.
In general, and we've seen that actually across the board, MRD tends to underestimate the overall impact on the primary endpoints, if it's PFS or EFS. Again, that gives us quite a bit of confidence that this 42% delta that we saw at the interim analysis actually is leading towards a likely positive study.
Okay. And if this is positive, either at the interim or final, correct me if I'm wrong, this is EFS, event-free survival. And to what extent is EFS a FDA regulatory approvable endpoint in this setting? Do you need full survival? Because if you go look back at some of the others, like BREYANZI and YESCARTA in the second line, where they beat transplant, pretty impressive data, we may add, they did have a survival benefit, if I recall.
YESCARTA did.
YESCARTA.
BREYANZI has not.
BREYANZI just barely missed. Can we be very confident that that will serve as a regulatory endpoint in this healthier population versus, say, third and fourth line, where they were approving things on just response rates?
Yes, of course, in designing this trial with regulators, of course, we wanted to pick an endpoint that was agreed, that would lead to an approval. EFS is the endpoint that we have agreed with FDA that will support approval of cema-cel. That will need to be also corroborated by PFS. By the way, EFS and PFS differ in only one component. It is a composite endpoint. The EFS includes new anti-lymphoma therapy in addition to disease progression or death from any cause. EFS and PFS are very closely related.
What would be new and why would that come up?
If somebody decided to treat a patient based on some suspicion that the disease was recurring in the absence of documented radiographic progression.
That's crazy. Someone's giving them a drug, but there's no documented evidence of a progression.
Look, if you've got a patient who's MRD positive and you believe that MRD positivity, as you and I clearly do, is indicative of residual disease, and then a patient comes to the clinic saying, "I've been having night sweats and fevers and so forth," you scan them and there's no evident disease progression. You may actually decide to treat them.
I don't know who would do that, but I don't know.
It's unlikely to happen very often.
There shouldn't be a big difference between EFS.
But it's an important moment for the patient, which is why it was included in EFS.
Okay.
To answer your question, is it a validated endpoint? Both BREYANZI and YESCARTA were approved based on EFS in the second line. With respect to OS, do we need to show an OS benefit? That is expressly not required by the FDA.
Yeah.
The only thing that we need to show is that there's not a decrement in OS. We do need to show that we're not actively shortening patients' lives, of course, but we do not need to show a benefit. That is going to be very hard to do in a frontline lymphoma context, because those patients, most of them are cured with frontline therapy. So, it's very hard to really show an OS benefit.
One of the things, we're asking all these relevant questions. One of the other relevant questions that came up is, we've asked hematologists, "Okay, well, as you think about this novel indication, consolidation, so it's almost like that breast cancer study with the SERDs, where you're treating someone before the ESR1 mutation occurs. Here, you're trying to treat someone before their cancer comes back." This is a little bit like an adjuvant type of setting. Yeah.
Adjuvant is a word I use interchangeably.
Exactly.
It doesn't generally apply to malignancies, but it's the same concept.
Right. Here, they would say, "Okay, but wait a second. If the cancer came back, we could just treat them right away with a documented, well-accepted survival benefit with YESCARTA." You got to go to the patient and tell them, "We're not going to treat you because we just wait till your cancer comes back." Adjuvant is to slow the time for the cancer to come back. One should not have any concerns about people just saying, "Okay, well, wait, we could just wait to treat later.
I think that's pretty unlikely, Mike. Not only do you then you have to have that conversation with the patient basically saying, "Look, I see evidence of residual disease here that we're just going to sit on and wait for the disease to come back and hope it doesn't come back in some way that renders you ineligible for CAR T.
I feel like the doctors probably wouldn't say that. They just don't even get into those details. They go, "Oh, we keep treating.
I mean, the question is, why would they send the test, right? I mean, that's the thing.
They just test you for anything and thenâ
You hope it's going to be negative, right?
They don't tell you what the results are. Yeah.
Yeah. But the idea is that cema-cel would be an option if it comes back positive. The other reason really here is tox.
Well, they're giving the test such that that doctor would be interested in using that.
Correct.
They're not randomly testing people with no plans to use this drug.
Well, it's exactly. I mean, the availability of a drugâ
Yeah.
âthat will give you something to do. A positive result is definitely going to increase utilization of MRD.
For sure. Because it is not, just to be clear, a standard test. There is no reason to.
People are using it increasingly now because they hope it is going to be negative.
That does add to the prognosis of the patient.
Is it reimbursed?
In some cases, yes. In some cases, no. It's very spotty because there's no data yet. ALPHA3, of course, would provide that data. I did want to comment on why you would treat early versus late, and that is the toxicity. What we are seeing in this early look in the ALPHA3 study is that if you can manage this fully as outpatientâ
Right.
âsometimes we call it the seventh cycle of treatment after the six cycles of R-CHOP, and these patients don't get admitted and they don't have a treatment-related mortality, they don't get big infections, that is a very attractive opportunity for patients rather than waiting for a disease recurrence, in which case you then get the full suite of risk around toxicity ofâ
Right.
âbig infections, CRS, ICANS, and so forth.
Yeah. I think that's an important point because administering this CAR T therapy, the side effect and toxicity profile in this setting, and I want to use your word benign, is significantly different. You just said there was no CRS, none of these issues are popping up. Biologically speaking, it shouldn't be shocking because the tumor burden is very low.
Exactly.
They're not having some wild reaction to a huge tumor burden. That is very different than in second and third line where you have significant cancer. That's why you're getting those results. When you wait for second-line metastatic, they do have CRS and all these other issues. We know that. The risk-benefit is significantly positive to treat, but you are putting people at risk of that.
Right.
That would be a reason why someone may not. Now, if they do get it, that's also the question, like, well, do they want to get CAR T again and then CAR T again? That shouldn't be an issue in this setting either, because in one case, that's ideal because, well, you don't want to give a CAR T and a CAR T again because of the toxicity. You're putting them at risk of toxicity twice. That is not the case in this.
Certainly, the toxicity is not of high concern in that context. If a patient does recur after cema-cel, of course, they would be evaluated for a host of second-line regimens, only one of which would be CAR T.
Right.
There is anecdotal evidence out there that patients actually can respond to an autologous CAR after an allogeneic, so we're not so concerned about that. But of course, most of these patients are not going to be offered CAR T anyway, which is the other answer to your question about why do it this way.
As opposed to waiting for relapse. Because we can actually truly do this in the community where CAR T is not available.
These are now patients that are having access to a CAR T product for the first time ever.
Therefore, our likelihood of actually improving disease outcomes is substantially increasedâ
Yep.
âsimply because we are treating more patients.
Fantastic. I know we're over time, I didn't get a chance to necessarily delve into it, but the bottom line, 60-second conclusion from the autoimmune data that you hosted a webcast on was that you treated a number of patients, including with no lymphodepletion, I think it was two patients, and that both patients at still lower doses still had significant reductions in B cells and symptom reduction. Is that fair?
That is correct. Yeah.
Okay, yeah. We need to treat more, and we need to test durability. We're going up to higher doses?
Correct.
Okay. When will be the next update?
Probably in the next few months. We haven't actually said exactly when, but we continue to enroll this trial very, very well. There's a high degree of interest by our investigators, so we've got a waiting list of patients to come in.
Okay.
We've got very encouraging data in diffuse cutaneous scleroderma, where the unmet need is really through the roof. To be able to demonstrate improvement to symptoms with no lymphodepletion at all, stopping all therapy and having a measure of time on no treatment whatsoever, with continued improvement in their scleroderma symptoms is really quite encouraging.
Particularly for these severe autoimmune diseasesâ
Yes.
âwhich provides a new option.
Yes.
Thank you very much, Zach. A pleasure to have you with us.
Thank you.
Thank you for spending time with us.
100%. Thank you.
Thanks, guys. Appreciate it.